Le SIDA en Afrique subsaharienne (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Identifieur interne : 002654 ( Main/Exploration ); précédent : 002653; suivant : 002655

Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Auteurs : Rengaswamy Sankaranarayanan [France] ; Rose Anorlu [Nigeria] ; Ghislain Sangwa-Lugoma ; Lynette A. Denny [Afrique du Sud]

Source :

RBID : pubmed:24331747

Descripteurs français

English descriptors

Abstract

The availability of both human papillomavirus (HPV) vaccination and alternative screening tests has greatly improved the prospects of cervical cancer prevention in sub-Saharan African (SSA) countries. The inclusion of HPV vaccine in the portfolio of new vaccines offered by the Gobal Alliance for Vaccines and Immunization (GAVI) to GAVI-eligible countries has vastly improved the chances of introducing HPV vaccination. Further investments to improve vaccine storage, distribution and delivery infrastructure and human resources of the Extended Programme of Immunization will substantially contribute to the faster introduction of HPV vaccination in SSA countries through both school- and campaign-based approaches. Alternative methods to cytology for the prevention of cervical cancer through the early detection and treatment of cervical cancer precursors have been extensively evaluated in the past 15 years, in Africa as well as in other low-resource settings. Visual inspection with 3-5% dilute acetic acid (VIA) and HPV testing are the two alternative screening methods that have been most studied, in both cross-sectional and randomised clinical trials. VIA is particularly suitable to low-resource settings; however, its efficacy in reducing cervical cancer is likely to be significantly lower than HPV testing. The introduction of VIA screening programmes will help develop the infrastructure that will, in turn, facilitate the introduction of affordable HPV testing in future. Links with the existing HIV/AIDS control programmes is another strategy to improve the infrastructure and screening services in SSA. Infrastructural requirements for an integrated approach aiming to vaccinate single-year cohorts of girls in the 9-13 years age-range and to screen women over 30 years of age using VIA or affordable rapid HPV tests are outlined in this manuscript. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in the Sub-Saharan Africa Region" Vaccine Volume 31, Supplement 5, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.

DOI: 10.1016/j.vaccine.2012.06.066
PubMed: 24331747


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.</title>
<author>
<name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name>
<affiliation wicri:level="3">
<nlm:affiliation>Early Detection and Prevention Section and Screening Group, International Agency for Research on Cancer (WHO-IARC), Lyon, France. Electronic address: SankarR@iarc.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Early Detection and Prevention Section and Screening Group, International Agency for Research on Cancer (WHO-IARC), Lyon</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Anorlu, Rose" sort="Anorlu, Rose" uniqKey="Anorlu R" first="Rose" last="Anorlu">Rose Anorlu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Oncology and Pathological Studies Unit, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria.</nlm:affiliation>
<country xml:lang="fr">Nigeria</country>
<wicri:regionArea>Oncology and Pathological Studies Unit, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos</wicri:regionArea>
<wicri:noRegion>Lagos</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sangwa Lugoma, Ghislain" sort="Sangwa Lugoma, Ghislain" uniqKey="Sangwa Lugoma G" first="Ghislain" last="Sangwa-Lugoma">Ghislain Sangwa-Lugoma</name>
<affiliation>
<nlm:affiliation>Groupe de Recherche en Santé, Faculté Saint-Jean, University of Alberta, Edmonton, Canada and Department of Obstetrics and Gynaecology, University of Kinshasa, Kinshasa, Democratic Republic of Congo, Congo.</nlm:affiliation>
<wicri:noCountry code="subField">Congo</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Denny, Lynette A" sort="Denny, Lynette A" uniqKey="Denny L" first="Lynette A" last="Denny">Lynette A. Denny</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department Obstetrics and Gynaecology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Department Obstetrics and Gynaecology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:24331747</idno>
<idno type="pmid">24331747</idno>
<idno type="doi">10.1016/j.vaccine.2012.06.066</idno>
<idno type="wicri:Area/PubMed/Corpus">001270</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001270</idno>
<idno type="wicri:Area/PubMed/Curation">001270</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001270</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001270</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001270</idno>
<idno type="wicri:Area/Ncbi/Merge">002588</idno>
<idno type="wicri:Area/Ncbi/Curation">002588</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002588</idno>
<idno type="wicri:Area/Main/Merge">002661</idno>
<idno type="wicri:Area/Main/Curation">002654</idno>
<idno type="wicri:Area/Main/Exploration">002654</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.</title>
<author>
<name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name>
<affiliation wicri:level="3">
<nlm:affiliation>Early Detection and Prevention Section and Screening Group, International Agency for Research on Cancer (WHO-IARC), Lyon, France. Electronic address: SankarR@iarc.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Early Detection and Prevention Section and Screening Group, International Agency for Research on Cancer (WHO-IARC), Lyon</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Anorlu, Rose" sort="Anorlu, Rose" uniqKey="Anorlu R" first="Rose" last="Anorlu">Rose Anorlu</name>
<affiliation wicri:level="1">
<nlm:affiliation>Oncology and Pathological Studies Unit, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos, Nigeria.</nlm:affiliation>
<country xml:lang="fr">Nigeria</country>
<wicri:regionArea>Oncology and Pathological Studies Unit, Department of Obstetrics and Gynaecology, College of Medicine, University of Lagos, Lagos University Teaching Hospital, Lagos</wicri:regionArea>
<wicri:noRegion>Lagos</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Sangwa Lugoma, Ghislain" sort="Sangwa Lugoma, Ghislain" uniqKey="Sangwa Lugoma G" first="Ghislain" last="Sangwa-Lugoma">Ghislain Sangwa-Lugoma</name>
<affiliation>
<nlm:affiliation>Groupe de Recherche en Santé, Faculté Saint-Jean, University of Alberta, Edmonton, Canada and Department of Obstetrics and Gynaecology, University of Kinshasa, Kinshasa, Democratic Republic of Congo, Congo.</nlm:affiliation>
<wicri:noCountry code="subField">Congo</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Denny, Lynette A" sort="Denny, Lynette A" uniqKey="Denny L" first="Lynette A" last="Denny">Lynette A. Denny</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department Obstetrics and Gynaecology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town, South Africa.</nlm:affiliation>
<country xml:lang="fr">Afrique du Sud</country>
<wicri:regionArea>Department Obstetrics and Gynaecology, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town/Groote Schuur Hospital, Cape Town</wicri:regionArea>
<wicri:noRegion>Cape Town</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Vaccine</title>
<idno type="eISSN">1873-2518</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Africa South of the Sahara</term>
<term>Diagnostic Services (organization & administration)</term>
<term>Early Detection of Cancer (methods)</term>
<term>Female</term>
<term>Health Services Administration</term>
<term>Humans</term>
<term>Papillomavirus Infections (complications)</term>
<term>Papillomavirus Infections (diagnosis)</term>
<term>Papillomavirus Infections (prevention & control)</term>
<term>Papillomavirus Vaccines (administration & dosage)</term>
<term>Primary Prevention (organization & administration)</term>
<term>Uterine Cervical Neoplasms (diagnosis)</term>
<term>Uterine Cervical Neoplasms (prevention & control)</term>
<term>Vaccination (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Administration des services de santé</term>
<term>Afrique subsaharienne</term>
<term>Détection précoce de cancer ()</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus ()</term>
<term>Infections à papillomavirus (diagnostic)</term>
<term>Prévention primaire (organisation et administration)</term>
<term>Services de diagnostic (organisation et administration)</term>
<term>Tumeurs du col de l'utérus ()</term>
<term>Tumeurs du col de l'utérus (diagnostic)</term>
<term>Vaccination ()</term>
<term>Vaccins contre les papillomavirus (administration et posologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Papillomavirus Vaccines</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en">
<term>Africa South of the Sahara</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Vaccins contre les papillomavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Papillomavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Papillomavirus Infections</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr">
<term>Infections à papillomavirus</term>
<term>Tumeurs du col de l'utérus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Early Detection of Cancer</term>
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr">
<term>Prévention primaire</term>
<term>Services de diagnostic</term>
</keywords>
<keywords scheme="MESH" qualifier="organization & administration" xml:lang="en">
<term>Diagnostic Services</term>
<term>Primary Prevention</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Papillomavirus Infections</term>
<term>Uterine Cervical Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Female</term>
<term>Health Services Administration</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Administration des services de santé</term>
<term>Afrique subsaharienne</term>
<term>Détection précoce de cancer</term>
<term>Femelle</term>
<term>Humains</term>
<term>Infections à papillomavirus</term>
<term>Tumeurs du col de l'utérus</term>
<term>Vaccination</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The availability of both human papillomavirus (HPV) vaccination and alternative screening tests has greatly improved the prospects of cervical cancer prevention in sub-Saharan African (SSA) countries. The inclusion of HPV vaccine in the portfolio of new vaccines offered by the Gobal Alliance for Vaccines and Immunization (GAVI) to GAVI-eligible countries has vastly improved the chances of introducing HPV vaccination. Further investments to improve vaccine storage, distribution and delivery infrastructure and human resources of the Extended Programme of Immunization will substantially contribute to the faster introduction of HPV vaccination in SSA countries through both school- and campaign-based approaches. Alternative methods to cytology for the prevention of cervical cancer through the early detection and treatment of cervical cancer precursors have been extensively evaluated in the past 15 years, in Africa as well as in other low-resource settings. Visual inspection with 3-5% dilute acetic acid (VIA) and HPV testing are the two alternative screening methods that have been most studied, in both cross-sectional and randomised clinical trials. VIA is particularly suitable to low-resource settings; however, its efficacy in reducing cervical cancer is likely to be significantly lower than HPV testing. The introduction of VIA screening programmes will help develop the infrastructure that will, in turn, facilitate the introduction of affordable HPV testing in future. Links with the existing HIV/AIDS control programmes is another strategy to improve the infrastructure and screening services in SSA. Infrastructural requirements for an integrated approach aiming to vaccinate single-year cohorts of girls in the 9-13 years age-range and to screen women over 30 years of age using VIA or affordable rapid HPV tests are outlined in this manuscript. This article forms part of a regional report entitled "Comprehensive Control of HPV Infections and Related Diseases in the Sub-Saharan Africa Region" Vaccine Volume 31, Supplement 5, 2013. Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Afrique du Sud</li>
<li>France</li>
<li>Nigeria</li>
</country>
<region>
<li>Auvergne-Rhône-Alpes</li>
<li>Rhône-Alpes</li>
</region>
<settlement>
<li>Lyon</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Sangwa Lugoma, Ghislain" sort="Sangwa Lugoma, Ghislain" uniqKey="Sangwa Lugoma G" first="Ghislain" last="Sangwa-Lugoma">Ghislain Sangwa-Lugoma</name>
</noCountry>
<country name="France">
<region name="Auvergne-Rhône-Alpes">
<name sortKey="Sankaranarayanan, Rengaswamy" sort="Sankaranarayanan, Rengaswamy" uniqKey="Sankaranarayanan R" first="Rengaswamy" last="Sankaranarayanan">Rengaswamy Sankaranarayanan</name>
</region>
</country>
<country name="Nigeria">
<noRegion>
<name sortKey="Anorlu, Rose" sort="Anorlu, Rose" uniqKey="Anorlu R" first="Rose" last="Anorlu">Rose Anorlu</name>
</noRegion>
</country>
<country name="Afrique du Sud">
<noRegion>
<name sortKey="Denny, Lynette A" sort="Denny, Lynette A" uniqKey="Denny L" first="Lynette A" last="Denny">Lynette A. Denny</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002654 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002654 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaSubSaharaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:24331747
   |texte=   Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:24331747" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SidaSubSaharaV1 

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Mon Nov 13 19:31:10 2017. Site generation: Wed Mar 6 19:14:32 2024